AbstractPurpose This article provides an overview of the scientific content on tirbanibulin 1% ointment, summarizing key phase IV results and real-life experiences with tirbanibulin shared by dermatologists across Europe. Materials and Methods Summary of posters, oral presentation and symposium discussions related to tirbanibulin presented at the 11th World Congress of Melanoma in conjunction with 21st European Association of Dermato Oncology (EADO) Congress held between 3rd and 5th of April 2025 in Athens, Greece. Results We report presented data on the efficacy/effectiveness, safety and tolerability of tirbanibulin 1% ointment for the treatment of actinic keratosis (AK) on the face, scalp and décolleté. We also collected evidence supporting its use in AK in organ transplant recipients (OTR), solar damaged skin, pigmented AK (PAK), proliferative AK, hypertrophic AK, actinic cheilitis (AC), keratinocyte carcinoma (KC) and lentigo maligna (LM). Conclusions Overall, data from a phase IV trial and real-world clinical practice suggest that tirbanibulin is an effective, safe and well-tolerated treatment for AK. Tirbanibulin may also be an option for OTR, patients with PAK, proliferative or hypertrophic AK, and even for conditions such as AC or KC, although the sample size is small in some of these groups and further evidence is needed.
Ardigo et al. (Thu,) studied this question.